Takeda's Ninlaro combo fails to hit main goal in newly diagnosed, transplant ineligible multiple myeloma

Takeda has unveiled new Phase 3 data for its oral proteasome inhibitor Ninlaro (ixazomib) in the treatment of newly diagnosed transplant ineligible multiple myeloma, revealing that the therapy, when combined [...]